Prager et al. [9] note that patients with primary hyperparathyroidism have both a diminished glucose-lowering effect of intravenous insulin compared with controls (p < 0.01) and insulin binding (p < 0.01), which the authors conclude is likely due to the downregulation of insulin receptors. Here, INS is linked to primary hyperparathyroidism.